Summary

In patients with diabetes, vascular conditions are responsible for the majority of morbidity, mortality, and cost that are attributed to the disease [Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2007]. The Liraglutide Effect and Action in Diabetes [LEAD; NCT00700817] trials are designed to evaluate the efficacy and safety of glucagon-like peptide-1 agonist compared with existing antidiabetic therapies.